Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)
Sponsor: University of Florence
Summary
A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved. The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\_5)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2024-10-30
Completion Date
2026-10-30
Last Updated
2026-01-21
Healthy Volunteers
No
Conditions
Interventions
Eptinezumab 100 or 300 mg ev
Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.
Locations (1)
Campus Biomedico
Roma, Italy